Stay updated on Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page
- Check4 days agoChange DetectedAdded the NEJM 2015 paper by Larkin et al. on Combined Nivolumab and Ipilimumab for untreated melanoma; removed the Erratum entry for that publication.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check33 days agoChange DetectedPublications section updated: two new articles added and one article removed.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-government-funding notice and Revision: v3.4.1.SummaryDifference0.4%

- Check61 days agoChange DetectedAdded a Publications reference for Larkin et al. (Combined Nivolumab and Ipilimumab in untreated melanoma) replacing the older Larkin et al. NEJM citation, and a site-wide notice about government funding and NIH status was also added.SummaryDifference0.4%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.